» Articles » PMID: 28249652

Validation of the ICON-S Staging for HPV-associated Oropharyngeal Carcinoma Using a Pre-defined Treatment Policy

Overview
Journal Oral Oncol
Publisher Elsevier
Specialty Dentistry
Date 2017 Mar 3
PMID 28249652
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To determine whether the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) for HPV associated oropharyngeal carcinoma (HPV+OPC) is a better discriminator of overall survival (OS), compared with the 7th edition (7th Ed) AJCC/UICC TNM staging following curative radiotherapy (RT).

Material And Methods: The 5-year OS for all patients with non-metastatic (M0) p16-confirmed OPC treated between 2005 and 2015 was determined and grouped based on the 7th Ed AJCC/UICC TNM and ICON-S staging.

Results: A total of 279 patients met the inclusion criteria. The 5-year OS with the 7th Ed TNM classification were Stage I/II 88.9% (95% CI; 70.6-100%), Stage III 93.8% (95% CI; 85.9-100%), Stage IVa 86.4% (95% CI; 81.6-91.5%) and Stage IVb 62.3% (95% CI; 46.8-82.8%). On multivariate Cox regression analysis there was no statistically significant OS difference when comparing Stage I/II with, Stage III (p=0.98, HR=0.97, 95% CI; 0.11-8.64), IVa (p=0.67, HR=1.56, 95% CI; 0.2-11.94) and IVb (p=0.11, HR=5.54, 95% CI; 0.69-44.52), respectively. The 5-year OS with ICON-S staging were Stage I 93.6% (95% CI; 89.4-98.0%), Stage II 81.9% (95% CI; 73.7-91.1%) and Stage III 69.1% (95%; 57.9-82.6%). There was a consistent decrease of OS with increasing stage. On multivariate Cox regression analysis, when compared to Stage I, OS was significantly lower for stage II (p=0.007, HR=2.84, 95% CI; 1.33-6.05) and stage III (p<0.001, HR=3.78, 95% CI; 1.81-7.92), respectively.

Conclusion: The ICON-S staging provides better OS stratification for HPV+OPC following RT compared with the 7th Ed TNM staging.

Citing Articles

Prognostic Significance of Bulky Nodal Disease in Anal Cancer Management: A Multi-institutional Study.

Chun S, Kim E, Jang W, Kim M, Kang H, Kim B Cancer Res Treat. 2024; 56(4):1197-1206.

PMID: 38605662 PMC: 11491260. DOI: 10.4143/crt.2024.258.


Importance of the Number and Location of Lymph Node Metastasis in Oropharyngeal Cancer.

Iida M, Murai T, Kuno M, Osumi K, Nakanishi-Imai M, Okazaki D In Vivo. 2023; 37(5):2210-2218.

PMID: 37652496 PMC: 10500500. DOI: 10.21873/invivo.13321.


An evaluation of an innovative screening program based on risk criteria for early diagnosis of head and neck cancers.

Zabala A, Martin-Arregui F, Sagazola J, Santaolalla F, Santaolalla F Front Public Health. 2023; 10:1004039.

PMID: 36699893 PMC: 9868380. DOI: 10.3389/fpubh.2022.1004039.


Importance of lymph node ratio in HPV-related oropharyngeal cancer patients treated with surgery and adjuvant treatment.

Choi K, Song J, Hong J, Lee Y, Kang J, Sun D PLoS One. 2022; 17(8):e0273059.

PMID: 35960785 PMC: 9374241. DOI: 10.1371/journal.pone.0273059.


Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas.

Vijayvargiya P, Trivedi S, Rupji M, Song H, Liu Y, Jiang R Oncologist. 2022; 27(1):48-56.

PMID: 35305095 PMC: 8842371. DOI: 10.1093/oncolo/oyab001.